

Oral presentation

Open Access

## OA05-04. Gp96-Ig-SIV vaccines induce predominant immune responses at mucosal sites

N Strbo\*<sup>1</sup>, M Vaccari<sup>2</sup>, S Pahwa<sup>1</sup>, MA Kolber<sup>1</sup>, E Fisher<sup>1</sup>, L Gonzalez<sup>1</sup>, BK Felber<sup>2</sup>, GN Pavlakis<sup>2</sup>, G Franchini<sup>2</sup> and ER Podack<sup>1</sup>

Address: <sup>1</sup>Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL, USA and <sup>2</sup>NCI/NIH, Bethesda, MD, USA

\* Corresponding author

from AIDS Vaccine 2009  
Paris, France. 19–22 October 2009

Published: 22 October 2009

Retrovirology 2009, 6(Suppl 3):O34 doi:10.1186/1742-4690-6-S3-O34

This abstract is available from: <http://www.retrovirology.com/content/6/S3/O34>

© 2009 Strbo et al; licensee BioMed Central Ltd.

### Background

We have developed a vaccine design that utilizes the unique property of the endoplasmic reticulum chaperon, heat shock protein (HSP) gp96, to bind antigenic peptides and deliver them to APCs. Cell-based gp96-Ig vaccines, by prolonged *in vivo* secretion of gp96-Ig peptide, imitate viral replication and provide immune stimuli comparable to attenuated viruses. In model systems in mice we have shown that gp96-Ig transfected, antigen expressing cells secrete gp96-Ig *in vivo* and stimulate both systemic and strong mucosal immunity. The aim of our study was to evaluate safety and systemic and mucosal SIV-immunity with secreted gp96-Ig-SIV vaccines in non-human primates.

### Methods

Gp96-Ig was generated by replacing the ER retention sequence KDEL with the IgG1-Fc tag. HEK-293 cells were transfected with gp96-Ig and with the cDNAs encoding the SIV antigens gag, pol, env and retnef. Irradiated, transfected 293 cells that secrete 1, 5 or 50 micrograms gp96-Ig-SIV-peptide complexes in 24 h, were injected intraperitoneally in Mamu-A\*01+ macaques at 0, 4 and 25 weeks.

### Results

After the third immunization the SIV-specific CD8 response was boosted to very high levels in the rectum and jejunum (30 – 50% tetramer positive cells in the CD8 gate in LPL and IEL). In vaginal IEL gag-specific CD8

responses reached 4%. Tetramer+ cells expressed appropriate functional (granzymeB) and migration markers (CD103). Control macaques immunized with 293 cells not secreting gp96, showed only background tetramer binding. The mucosal CD8+ and CD4+ T cells from lamina propria and intraepithelial compartment secrete IL-2 or IFN-gamma or both simultaneously in response to peptide stimulation.

### Conclusion

We conclude that the cell secreted gp96-Ig-SIV vaccine is safe and can induce strong poly-specific, multifunctional and predominant CD8 responses in mucosal compartments that are thought to be critical for protection from SIV/HIV infection.

Public Health Service Grants R21 AI068515, R21/R33 AI073234, PO1 CA109094.